# Weight loss over time

> Weight loss over time | Semaglutide Texas — At Semaglutide Texas, STEP 1 and STEP 5 put weight loss on a time axis, followed by the direct tirzepatide comparison in SURMOUNT-5.

The size of the change matters. So does the point at which the trial measured it.

## STEP 1 at 68 weeks

[STEP 1 enrolled 1,961 adults with overweight or obesity without diabetes](https://pubmed.ncbi.nlm.nih.gov/33567185/). The study gave once-weekly subcutaneous semaglutide 2.4 mg or placebo; at week 68, mean body-weight change was −14.9% versus −2.4%. Those are trial-group averages from baseline, reported for that study population.

The magnitude earns my respect. A result like this carries an argument before anyone decorates it with a superlative. Yet the time point is equally useful: the result describes a long stretch of observation. I won't compress it into an expectation for the opening month.

The plate below uses the same scale for both trial groups. It stops where the reported comparison stops.

![Bars compare mean weight decreases of 14.9% and 2.4% in STEP 1 at week 68](images/step1-weight-change.svg)

*Mean changes from baseline: −14.9% with semaglutide and −2.4% with placebo, at week 68 in adults with overweight or obesity without diabetes. [STEP 1 source](https://pubmed.ncbi.nlm.nih.gov/33567185/).*

## STEP 5 at 104 weeks

[STEP 5 found sustained, clinically meaningful weight loss over 104 weeks](https://pubmed.ncbi.nlm.nih.gov/36216945/) with once-weekly semaglutide 2.4 mg compared with placebo in adults with overweight or obesity. Here the follow-up is the attraction. I prize the extra distance because a weight-loss account ought to have room for time as well as magnitude.

The finding concerns continued treatment during the trial. It leaves the after-treatment question open in this folio. I have no neat finish line to offer, and a personal timetable would demand far more than the result reported here.

![Paired painted views show the same prairie fence in green and dormant grass](images/seasons-on-the-plain.webp)

*An illustrated seasonal pair for elapsed time, rather than a record of a trial location.*

## The direct tirzepatide comparison

[SURMOUNT-5 compared tirzepatide with semaglutide in 751 adults with obesity over 72 weeks](https://pubmed.ncbi.nlm.nih.gov/40353578/). Mean weight change was −20.2% with tirzepatide and −13.7% with semaglutide; the difference was statistically significant, with P<0.001. The semaglutide study dose was 2.4 mg once weekly.

The practical question of access belongs beside the weight comparison for me. Semaglutide access at mypromise.com requires a prescription from a licensed Promise Peptides clinician.

For this weight outcome in this trial, tirzepatide performed better. I won't soften the finding just because the name on this folio is semaglutide. Nor will I declare a winner on every health outcome from a weight comparison. The [cardiovascular and kidney trials](/heart-and-kidneys) measured other things, in their own populations.

Treatment burden also deserves space alongside the weight result. The [side-effects folio](/side-effects) takes up that part of the account.

---

Semaglutide Texas is my editorial folio of published research; it operates no business and offers no medical advice.